Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/gannex-announces-poster-presentation-of-positive-interim-12-week-results-from-phase-ii-clinical-trial-of-asc41-in-patients-with-biopsy-confirmed-mash-at-easl-congress-2024-302168053.html
https://www.prnewswire.com/news-releases/gannexs-strategic-partner-sagimet-biosciences-announces-positive-topline-results-from-phase-2b-fascinate-2-clinical-trial-of-denifanstat-in-biopsy-confirmed-f2f3-nash-302041397.html
https://www.prnewswire.com/news-releases/gannex-announces-positive-interim-results-from-52-week-phase-ii-clinical-trial-of-once-daily-asc41-tablet-in-patients-with-biopsy-confirmed-non-alcoholic-steatohepatitis-302024444.html
https://www.fiercebiotech.com/biotech/gannex-posts-midphase-data-nash-asset-center-trade-secret-row
https://endpts.com/ascletis-gannex-reports-positive-interim-phii-nash-data-after-scrapping-previous-mid-stage-rd-plans/
https://www.prnewswire.com/news-releases/gannex-published-phase-i-data-of-asc42-a-novel-farnesoid-x-receptor-agonist-on-the-journal-drugs-in-rd-301978015.html
https://www.prnewswire.com/news-releases/gannex-announces-the-completion-of-patient-enrollment-for-phase-ii-clinical-trial-of-asc42-an-fxr-agonist-for-primary-biliary-cholangitis-301881089.html
https://www.indianpharmapost.com/news/nafld-clinical-trial-activity-catching-up-in-china-but-lacks-substantial-domestic-participation-says-globaldata-13507
https://www.clinicaltrialsarena.com/news/gannex-primary-biliary-cholangitis/
https://www.prnewswire.com/news-releases/gannex-announces-first-subject-dosed-in-the-us-drug-drug-interaction-study-of-fxr-agonist-asc42-for-treatment-of-primary-biliary-cholangitis-301605747.html